H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Black Diamond Therapeutics to $11 from $12 and keeps a Buy rating on the shares following the Q1 report. The firm is cautious in ascribing value to BDTX-1535 in brain cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Black Diamond Therapeutics reports Q1 EPS (35c), consensus (43c)
- Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics announces changes to board of directors
- Black Diamond Therapeutics Revamps Board Leadership
- Black Diamond Therapeutics Announces Changes to Board of Directors
Questions or Comments about the article? Write to editor@tipranks.com